Clinical Trials
3 trialsNCT04328844 2026-03-30
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
Phase 1 Active not recruiting
NCT03636503 2025-02-06
Rituximab + Immunotherapy in Follicular Lymphoma
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT03147404 2019-12-30
MS100070-0177
Samsung Medical Center
Phase 2 Completed